Education
About Us
Working with TipRanks
Follow Us
BerGenBio ASA (BRRGF)
OTHER OTC:BRRGF
BRRGF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.03
Previous CloseN/A
Volume50.00
Average Volume (3M)0.00
Market Cap
$5.48M
Enterprise Value$512.30M
Total Cash (Recent Filing)$140.16M
Total Debt (Recent Filing)kr818.00K
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Aug 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding39,087,116
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)7.48
Price to Sales (P/S)0.00
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.41Price Target Upside16950.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
BerGenBio ASA News
PremiumCompany Announcements
BerGenBio Continues Strategic Review and Ends Bemcentinib Development
PremiumCompany Announcements
BerGenBio ASA Announces Virtual Annual General Meeting
PremiumCompany Announcements
BerGenBio ASA Approves 2024 Financial Statements Amid Strategic Review
PremiumCompany Announcements
BerGenBio’s Bemcentinib Shows Promise in AML Treatment
PremiumCompany Announcements
BerGenBio Engages Financial Advisor for Strategic Alternatives Exploration
PremiumCompany Announcements
BerGenBio Reports Q4 2024 Results Amid Strategic Shift
PremiumCompany Announcements
BerGenBio ASA Closes Cancer Study Amid Financial Challenges
PremiumCompany Announcements
BerGenBio ASA Discontinues Lung Cancer Study, Explores Strategic OptionsBulls Say, Bears Say
Bulls Say
Clinical TrialsBerGenBio launches dual-inhibitor trial with first patient enrolled, focusing on patients with lung adenocarcinoma.
Market OpportunitiesBerGenBio has an opportunity to capture market share by targeting the STK11 mutation in cancer, particularly relevant for lung cancer patients with significant unmet medical need.
Bears Say
Partnership ChallengesIn 2022, BerGenBio announced it would not continue the internal development of tilvestamab due to an inability to secure an attractive partnership on favorable terms.
Product Development IssuesADC Therapeutics informed BerGenBio that the therapeutic window for ADCT-601 is too narrow, likely due to toxicities, impacting its development.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
BRRGF FAQ
What was BerGenBio ASA’s price range in the past 12 months?
BerGenBio ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.
What is BerGenBio ASA’s market cap?
BerGenBio ASA’s market cap is $5.48M.
When is BerGenBio ASA’s upcoming earnings report date?
BerGenBio ASA’s upcoming earnings report date is Aug 20, 2025 which is in 56 days.
How were BerGenBio ASA’s earnings last quarter?
Currently, no data Available
Is BerGenBio ASA overvalued?
According to Wall Street analysts BerGenBio ASA’s price is currently Undervalued.
Does BerGenBio ASA pay dividends?
BerGenBio ASA does not currently pay dividends.
What is BerGenBio ASA’s EPS estimate?
BerGenBio ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BerGenBio ASA have?
BerGenBio ASA has 39,087,116 shares outstanding.
What happened to BerGenBio ASA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BerGenBio ASA?
Currently, no hedge funds are holding shares in BRRGF
Company Description
BerGenBio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
BRRGF Company Deck
BRRGF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment, with positive developments in the BGB16 study and financial management, but faced setbacks with program discontinuations and the CEO's upcoming departure.Read More>Technical Analysis
Bioxcel Therapeutics
―
Cellectar Biosciences
―
Fennec Pharmaceuticals
―
Geron
―
Kazia Therapeutics
―
Sorrento Therapeutics
―